Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» $1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
Submitted by
CP Staff
on June 28, 2018 - 9:30am
Source:
CP Wire
News Tags:
Akebia Therapeutics
Keryx
kidney disease
M&A
vadadustat
Headline:
$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease
snippet:
Combined company will be named Akebia Therapeutics, Inc.
Company will focus on patients with chronic kidney disease
Combined portfolio can address the needs of an estimated 1.7 million patients in US subject to approval of vadadustat
Do Not Allow Advertisers to Use My Personal information
